Skip to main content

Table 3 Univariate and multivariate models of ORR for patients categorized according to their mutations (N = 76 (measured in 76 patients who had detectable gene mutations))

From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

 

Univariate models

Multivariate models

OR (95% Cl)

P value

OR (95% Cl)

P value

Category

 Other mutations

1.0

 

1.0

 

 Mutations in panel ET#

3.73 (1.43, 9.73)

0.0070

4.45 (1.46, 13.50)

0.0085

Age

1.03 (0.99, 1.07)

0.0920

1.04 (0.99, 1.08)

0.1351

Sex

 Male

1.0

 

1.0

 

 Female

0.43 (0.17, 1.11)

0.0823

0.39 (0.13, 1.21)

0.1035

BM blasts

0.13 (0.02, 0.80)

0.0275

0.32 (0.04, 3.01)

0.3218

HB

1.02 (1.00, 1.04)

0.0244

1.01 (0.99, 1.04)

0.2979

WBC

1.00 (0.98, 1.03)

0.9117

  

PLT

1.01 (1.00, 1.01)

0.1566

  

ECOG PS

 0

1.0

   

 1

0.24 (0.08, 0.78)

0.0169

  

 2

0.73 (0.19, 2.90)

0.6580

  

 3

0.00 (0.00, Inf)

0.9913

  

Diagnosis

 Refractory

1.0

 

1.0

 

 Early relapse

2.00 (0.69, 5.78)

0.2002

1.81 (0.51, 6.47)

0.3600

 Late relapse

4.27 (1.09, 16.83)

0.0377

4.91 (0.90, 26.80)

0.0663

Prior therapies

 0–5

1.0

   

 6–10

1.32 (0.48, 3.66)

0.5912

  

 ≥ 11

1.87 (0.49, 7.18)

0.3588

  
  1. Abbreviations: OR odds ratio, CI confidence interval, BM bone marrow, HB hemoglobin, WBC white blood cell count, PLT platelets, ECOG PS Eastern Cooperative Oncology Group performance score
  2. #Panel ET: epigenetic modifier-related or transcription factor-related gene mutations, but without FLT3-ITD co-mutation
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us